Sucampo announces commercial availability of Rescula in U.S. pharmacies Sucampo Pharmaceuticals announced that Rescula 0.15% is now available by prescription across the United States. The FDA approved a sNDA for Rescula for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension on December 7, 2012.
News For SCMP From The Last 14 Days
Check below for free stories on SCMP the last two weeks.
Sucampo to hold a pharmaceutical update meeting Pharmaceutical update to discuss the recent opioid-inducted constipation (OIC) indication approval for Sucampo's Amitiza is being held in Orlando, Florida on May 20 at 9 am. Webcast Link